This study of 3-(5-phenyl-1,3,4-oxadiazol-2-yl)-2H-chromen-2-one, C17H10N2O3, 1, and 3-[5-(pyridin-4-yl)-1,3,4-oxadiazol-2-yl]-2H-chromen-2-one, C16H9N3O3, 2, was performed on the assumption of the potential anticancer activity of the compounds. Three polymorphic structures for 1 and two polymorphic structures for 2 have been studied thoroughly. The strongest intermolecular interaction is stacking of the `head-to-head' type in all the studied crystals. The polymorphic structures of 1 differ with respect to the intermolecular interactions between stacked columns. Two of the polymorphs have a columnar or double columnar type of crystal organization, while the third polymorphic structure can be classified as columnar-layered. The difference between the two structures of 2 is less pronounced. Both crystals can be considered as having very similar arrangements of neighbouring columns. The formation of polymorphic modifications is caused by a subtle balance of very weak intermolecular interactions and packing differences can be identified only using an analysis based on a study of the pairwise interaction energies.
这项关于 3-(5-苯基-1,3,4-恶二唑-2-基)-2H-苯并吡喃-2-酮(C17H10N2O3,1)和 3-[5-(吡啶-4-基)-1,3,4-恶二唑-2-基]-2H-苯并吡喃-2-酮(C16H9N3O3,2)的研究是在假定这些化合物具有潜在抗癌活性的基础上进行的。对 1 的三种多态结构和 2 的两种多态结构进行了深入研究。在所有研究的晶体中,最强的分子间相互作用是 "头对头 "类型的堆积。1 的多态结构在堆叠柱之间的分子间相互作用方面有所不同。其中两种多晶型具有柱状或双柱状晶体结构,而第三种多晶型结构可归类为柱状层状结构。2 的两种结构之间的差异不太明显。可以认为这两种晶体具有非常相似的相邻柱状排列。多晶体修饰的形成是由非常微弱的分子间相互作用的微妙平衡造成的,只有通过研究成对相互作用能的分析才能确定堆积差异。